[ Price : $8.95]
FDA confirms that all drugs now have updated labeling to better provide health risk information to pregnant women.[ Price : $8.95]
California, Massachusetts, New Jersey, and New York ask FDA to cancel the mifepristone REMS program requirements in their states o...[ Price : $8.95]
FDA commissioner Marty Makary promises that the agency will listen to stakeholder ideas on reducing regulatory barriers and evolvi...[ Price : $8.95]
FDA warns Koreas DFI Co., Ltd. about Quality System and Medical Device Reporting violations in its manufacturing of reagent strips...[ Price : $8.95]
Three Morgan Lewis attorneys tell regulated product sponsors to watch for AI involvement in FDA reviews and be prepared to respond...[ Price : $8.95]
FDA announces three Class 1 recalls (device corrections) by Smiths Medical related to certain CADD [computerized ambulatory delive...[ Price : $8.95]
FDA warns Chinas Huangshi Hygienec Material Medicine Co. about CGMP violations in its manufacturing of finished drugs.[ Price : $8.95]
Vigil Neuroscience ends its Phase 2 long-term extension study of investigational therapy iluzanebart based on disappointing study ...